Plenum heralds China health policy changes but much still uncertain
This article was originally published in Scrip
There is no doubt that China will continue to push forward with its long-standing program of healthcare reforms, and following the country's recent "Third Plenum" – a major Central Committee meeting that sets general long-term growth strategy – it is clear that the next major changes could come as soon as next year.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.